RNA N6-methyladenosine (m6A) modification in HNSCC: molecular mechanism and therapeutic potential

Area of Science:

• Oncology
• Epigenetics
• Molecular Biology

Background:

• Head and neck squamous cell carcinoma (HNSCC) is a prevalent malignancy with limited treatment efficacy due to drug resistance.
• Current treatments for HNSCC, including surgery, radiotherapy, chemotherapy, targeted therapy, and immunotherapy, face challenges in improving patient survival rates.
• There is an urgent need for novel diagnostic and prognostic markers to overcome treatment resistance in HNSCC.

Purpose of the Study:

• To review the role of N6-methyladenosine (m6A) modification in the occurrence and development of HNSCC.
• To elucidate the mechanisms by which m6A modification contributes to drug resistance in HNSCC.
• To explore the implications of m6A modification in various HNSCC treatment modalities, including radiotherapy, chemotherapy, immunotherapy, and targeted therapy.

Main Methods:

• Literature review of studies investigating N6-methyladenosine modification in cancer.
• Analysis of research on the mechanisms of m6A 'writers', 'erasers', and 'readers' in tumor progression.
• Synthesis of findings related to m6A's impact on HNSCC treatment response and resistance.

Main Results:

• N6-methyladenosine modification is the most abundant epitranscriptomic modification in mammals and is implicated in tumor progression.
• m6A modification influences the development of HNSCC and is linked to resistance mechanisms against various therapies.
• Emerging research highlights m6A's significant role in radiotherapy, chemotherapy, immunotherapy, and targeted therapy for HNSCC.

Conclusions:

• N6-methyladenosine modification is a critical factor in HNSCC development and treatment resistance.
• Targeting m6A modification pathways presents a promising strategy for enhancing HNSCC treatment efficacy.
• Further investigation into m6A modification holds potential for improving overall survival and prognosis in HNSCC patients.